Clinical Trials Sponsored by Better Therapeutics

Total 56549 results

Better Therapeutics

Completed

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Type 2 Diabetes

United States
Better Therapeutics
Catalyst Health Network

Terminated

Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes

Type2 Diabetes

United States
Better Therapeutics
Mass General Brigham

Active, not recruiting

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus (ACTION-DM)

Diabetes Type 2

United States
Better Therapeutics
Arizona Liver Health

Completed

Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH

Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver

United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR)

Healthy

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Withdrawn

Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED) (INFUSE-TM)

Dehydration
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration (INFUSE-Cftrx)

Healthy
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT)

Dehydration

United States
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II)

Dehydration

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Terminated

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) (INFUSE-AT1A)

Dehydration

United States
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
Skyline Therapeutics (US) Inc.

Recruiting

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

China, United States
iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
CRISPR Therapeutics AG
ViaCyte

Recruiting

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Melinta Therapeutics, LLC

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Gram Positive Bacterial Infections

United States
TenNor Therapeutics Limited

Completed

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI)

Gram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial Infections

United States
CRISPR Therapeutics AG
ViaCyte

Completed

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Melinta Therapeutics, LLC

Recruiting

Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin

Acute Bacterial Skin and Skin Structure Infection

United States, Spain, Greece, Portugal, Bulgaria, Latvia, Romania, Lithuania, Poland
Windtree Therapeutics
CVie Therapeutics Co. Ltd.

Completed

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

China, Italy
Millendo Therapeutics SAS

Terminated

Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome (ZEPHYR)

Hyperphagia | Prader-Willi Syndrome

United States, Belgium, Spain, France, Italy, United Kingdom, Australia, Netherlands
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
Radboud University Medical Center
Endotools Therapeutics

Not yet recruiting

The GATE Study: Endoscopic Sutured Gastroplasty in Type 2 Diabetic, Obese Patients Using the Endomina Device (GATE)

Obesity | Diabete Type 2
AKARI Therapeutics
Radboud University Medical Center

Completed

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Paroxysmal Nocturnal Haemoglobinuria (PNH)

Netherlands
Fox Chase Cancer Center
WindMIL Therapeutics

Withdrawn

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

NSCLC | SCLC
Bronx VA Medical Center
Chelsea Therapeutics

Completed

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

Hypotension | Spinal Cord Injury

United States
M.D. Anderson Cancer Center
Alaunos Therapeutics

Completed

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Solid Tumors

United States
Luminary Therapeutics
Case Comprehensive Cancer Center

Recruiting

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin Lymphoma, B-Cell

United States
Alaunos Therapeutics
M.D. Anderson Cancer Center

Suspended

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Ovarian Cancer | Cholangiocarcinoma | Endometrial Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer

United States
Dartmouth-Hitchcock Medical Center
Disarm Therapeutics

Completed

Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity (CIPN)

CIPN - Chemotherapy-Induced Peripheral Neuropathy

United States
Fred Hutchinson Cancer Center
ADC Therapeutics

Withdrawn

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent High... and other conditions

United States
M.D. Anderson Cancer Center
Direct Therapeutics

Completed

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

Glioma | Brain Neoplasms

United States
Meir Medical Center
SpotOn Therapeutics Ltd.

Completed

Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness

Chronic Dizziness

Israel

Clinical Trials Sponsored by Better Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations